Myriad Genetics (MYGN) Share-based Compensation (2009 - 2026)

Myriad Genetics has disclosed Share-based Compensation across 18 years of filings, most recently posting $6.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 31.58% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $32.2 million (down 31.92% YoY), while the FY2025 annual figure was $35.2 million, down 29.32% from the prior year.
• Share-based Compensation rose to $6.5 million in Q1 2026, from $2.8 million in the prior quarter.
• Over the last five years, Share-based Compensation for MYGN reached as high as $14.5 million in Q2 2024 and fell as low as $2.8 million in Q4 2025.
• The 5-year median for Share-based Compensation is $10.4 million (2022), against an average of $10.0 million.
• Annual changes were most pronounced in 2024 — Share-based Compensation jumped 60.0% — and 2025, when it slumped 74.31%.
• A 5-year view of Share-based Compensation shows it stood at $8.2 million in 2022, then rose by 26.83% to $10.4 million in 2023, then grew by 4.81% to $10.9 million in 2024, then tumbled by 74.31% to $2.8 million in 2025, then jumped by 132.14% to $6.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $6.5 million, $2.8 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.